ClinicalTrials.gg
CompletedNCT01986114Updated Apr 12, 2022Results posted

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

A Phase 3 interventional study of SM-13496 in Bipolar I Disorder, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 8 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Study summary

The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I disorder.

Read the detailed description

The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120 mg/day) in patients with bipolar I disorder.

02

Conditions studied

  • Bipolar I Disorder
03

In context

Lead sponsor

Sumitomo Pharma Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who completed the D1002001 study

・Patients who completed the D1002001 study and who are considered by the investigator to be eligible and without safety concerns.

Patients who did not participate in the D1002001 study

  • Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.
  • Outpatients aged 18 through 74 years at the time of consent
  • Patients meets criteria for bipolar I disorder, most recent episode manic, hypomanic, or mixed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance, but \< 8 episodes in the previous 12 months prior to screening).

Exclusion criteria

Exclusion Criteria:

  • Patients with imminent risk of suicide or injury to self, others, or property.
  • Patients who are otherwise considered ineligible for the study by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
495 participants (actual)

Study arms

  • Experimental
    SM-13496 20-120mg

    once daily orally SM-13496 20-120 mg flexibly dosed

    Drug: SM-13496

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)

    The number and percentage of subjects with at least one adverse event and adverse drug reaction

    Time frame: 28, 52 weeks

Secondary outcomes

  1. Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score

    Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

    Time frame: Baseline, 52 weeks and each month

  2. Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.

    YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.

    Time frame: Baseline, 52 weeks and each month

  3. Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.

    The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.

    Time frame: Baseline to 52 weeks

07

Results

Posted Jul 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneSM-13496 20-120mg
Started495
Completed339
Not completed156
Withdrew: Adverse event59
Withdrew: Lack of efficacy23
Withdrew: Withdrawal by subject58
Withdrew: Noncompliance3
Withdrew: Protocol violation1
Withdrew: Lost to follow-up5
Withdrew: Other reason7

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)

The number and percentage of subjects with at least one adverse event and adverse drug reaction

Time frame:
28, 52 weeks
Reported as:
Count of participants · Participants
Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)
ParticipantsSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)352169
SecondaryChange From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score

Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

Time frame:
Baseline, 52 weeks and each month
Reported as:
Mean · units on a scale
Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score
units on a scaleSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score-4.4 ± 12.091.1 ± 12.58
SecondaryChange From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.

YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.

Time frame:
Baseline, 52 weeks and each month
Reported as:
Mean · units on a scale
Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.
units on a scaleSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.-1.0 ± 4.54-2.0 ± 6.73
SecondaryNumber of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.

The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.

Time frame:
Baseline to 52 weeks
Reported as:
Count of participants · Participants
Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.
ParticipantsSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.1418

Adverse events

Collected over Adverse event data was collected for 28 weeks (outside Japan) and 52 weeks (Japan).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SM-13496 20-120mg (Overall, 28 Weeks)0/495 (0%)19/495 (3.8%)250/495 (50.5%)
SM-13496 20-120mg (Japan, 52 Weeks)0/199 (0%)12/199 (6%)137/199 (68.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
Disease progressionGeneral disorders8/4953/199
Suicide attemptPsychiatric disorders3/4951/199
Pelvic fractureInjury, poisoning and procedural complications1/4951/199
Blood potassium decreasedInvestigations1/4951/199
Glucose urine presentInvestigations1/4951/199
Weight decreasedInvestigations1/4951/199
Diabetes mellitusMetabolism and nutrition disorders0/4951/199
Lactic acidosisMetabolism and nutrition disorders0/4951/199
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/4951/199
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4951/199
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSM-13496 20-120mg (Overall, 28 Weeks)SM-13496 20-120mg (Japan, 52 Weeks)
AkathisiaNervous system disorders91/49560/199
NasopharyngitisInfections and infestations51/49553/199
NauseaGastrointestinal disorders35/49524/199
SomnolenceNervous system disorders41/49524/199
Weight increasedInvestigations31/49517/199
HeadacheNervous system disorders37/49516/199
ParkinsonismNervous system disorders34/49515/199
VomitingGastrointestinal disorders17/49513/199
DiarrhoeaGastrointestinal disorders14/49510/199
Disease progressionGeneral disorders16/49510/199

Baseline characteristics

Safety population-received at least one dose of study medication

Age, Continuous
Age, Continuous(years)SM-13496 20-120mg
Mean42.6 ± 12.78
Sex: Female, Male
Sex: Female, Male(Participants)SM-13496 20-120mg
Female259
Male236
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SM-13496 20-120mg
American Indian or Alaska Native0
Asian225
Native Hawaiian or Other Pacific Islander0
Black or African American0
White270
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)SM-13496 20-120mg
Japan199
Philippines8
Taiwan7
Ukraine117
Malaysia11
Slovakia15
Lithuania9
Russia129
08

Study locations

8 sites
  • Japan 68 sites
    Tokyo, Japan
  • Lithuania 3 sites
    Kaunas, Lithuania
  • Malaysia 5 sites
    Kuala Lumpur, Malaysia
  • Philippines 5 sites
    Manila, Philippines
  • Russia 19 sites
    Moscow, Russian Federation
  • Slovakia 5 sites
    Zilina, Slovakia
  • Taiwan 8 sites
    Taipei, Taiwan
  • Ukraine 9 sites
    Kiev, Ukraine
09

References and documents

Publications

  • Higuchi T, Kato T, Miyajima M, Watabe K, Masuda T, Hagi K, Ishigooka J. Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study. Int J Bipolar Disord. 2021 Aug 2;9(1):25. doi: 10.1186/s40345-021-00230-8. PubMed 34342746 ↗
  • Ishigooka J, Kato T, Miyajima M, Watabe K, Masuda T, Hagi K, Higuchi T. Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. J Affect Disord. 2021 Feb 15;281:160-167. doi: 10.1016/j.jad.2020.12.005. Epub 2020 Dec 8. Erratum In: J Affect Disord. 2021 Sep 1;292:789. doi: 10.1016/j.jad.2021.06.004. J Affect Disord. 2022 Jan 15;297:687. doi: 10.1016/j.jad.2021.09.012. PubMed 33321381 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Feb 2018, 48 months.

Results were first posted in Jul 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2013
First posted
Nov 18, 2013
StartActual
Jan 29, 2014
Primary completionActual
Feb 8, 2018
CompletionActual
Feb 17, 2018
Results first posted
Jul 23, 2019
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986114
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Jan 29, 2014
Primary completion
Feb 8, 2018
Completion
Feb 17, 2018
Results posted
Jul 23, 2019
Last update
Apr 12, 2022

Study contacts

Director, Drug Development Division
study director · Sumitomo Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion